Synopsis:
Difficulties with safety monitoring during clinical trials in less-industrialized countries have hampered global research equity. Re-discussion of objectives and methods of safety monitoring and adapted general clinical practice guidelines may contribute to greater participation of these countries in the clinical trials industry.